Suppr超能文献

血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平可预测首次急性酒精性胰腺炎后长期死亡率。

Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.

机构信息

Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Teiskontie 35, 33521, Finland.

Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.

出版信息

Eur J Intern Med. 2019 Jun;64:72-75. doi: 10.1016/j.ejim.2019.04.007. Epub 2019 May 3.

Abstract

BACKGROUND

Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker associated with inflammatory and certain malignancies. Earlier we have shown that plasma suPAR (P-suPAR) predicts severity of acute alcohol-induced pancreatitis (AAP) on admission. Our aim was to investigate whether P-suPAR levels predict AAP recurrences or mortality during long-term follow-up after first AAP.

METHODS

Eighty-three patients (median age 47.5, range 25-71 years) suffering their first AAP during 2001-2005 were recruited and followed prospectively for 9 years with a median follow-up time of 7.0 (range 0.3-9.8) years. P-suPAR was measured by enzyme-linked immunosorbent assay (ELISA) from the samples taken at follow-up visits. Survival was registered in November 2014.

RESULTS

P-suPAR level on admission or after recovery of the first AAP did not predict the recurrence of AAP. However, higher P-suPAR measured after recovery of first AAP (3.6 vs. 2.9 ng/mL) predicted mortality during follow-up period (hazard ratio 1.48, p = .008). Cut-off value for P-suPAR indicating a higher risk for 10-year mortality resulted a value of ≥3.4 ng/mL. When adjusted for other covariates, P-suPAR above cut-off level retained its statistical significance as an independent factor.

CONCLUSIONS

P-suPAR level on admission or after recovery of the first AAP does not predict the recurrence of AAP during long-term follow-up. However, P-suPAR ≥3.4 mg/mL measured after recovery from first AAP is associated with an increased risk of 10-year mortality as an independent factor. This can be used to detect patients with highest risk after AAP, in order to focus the preventive healthcare actions.

摘要

背景

可溶性尿激酶型纤溶酶原激活物受体(suPAR)是与炎症和某些恶性肿瘤相关的生物标志物。我们之前的研究表明,血浆 suPAR(P-suPAR)可预测入院时急性酒精性胰腺炎(AAP)的严重程度。我们的目的是研究在首次 AAP 后进行的长期随访中,P-suPAR 水平是否可预测 AAP 的复发或死亡率。

方法

2001-2005 年间首次患有 AAP 的 83 名患者(中位年龄 47.5 岁,范围 25-71 岁)入选并进行前瞻性随访,中位随访时间为 7.0 年(范围 0.3-9.8 年)。在随访时通过酶联免疫吸附测定(ELISA)测量 P-suPAR。生存情况于 2014 年 11 月进行登记。

结果

入院时或首次 AAP 恢复后的 P-suPAR 水平均不能预测 AAP 的复发。然而,在首次 AAP 恢复后测量的较高的 P-suPAR(3.6 vs. 2.9ng/mL)预示着随访期间的死亡率(风险比 1.48,p=0.008)。P-suPAR 指示 10 年死亡率风险较高的截断值为≥3.4ng/mL。当调整其他协变量时,高于截断值的 P-suPAR 仍然是独立的预测因素。

结论

入院时或首次 AAP 恢复后的 P-suPAR 水平不能预测长期随访中的 AAP 复发。然而,在首次 AAP 恢复后测量的 P-suPAR 值≥3.4ng/mL 与 10 年死亡率风险增加相关,是一个独立的危险因素。这可用于检测 AAP 后风险最高的患者,以便集中进行预防保健措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验